Animal models of sepsis: Setting the stage

被引:666
作者
Buras, JA
Holzmann, B
Sitkovsky, M
机构
[1] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA
[2] Tech Univ Munich, Dept Surg, D-81675 Munich, Germany
[3] Northeastern Univ, Dept Biol, Consortium, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA
[4] Northeastern Univ, Dept Pharmaceut Sci, Consortium, New England Inflammat & Tissue Protect Inst, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nrd1854
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Sepsis is a state of disrupted inflammatory homeostasis that is often initiated by infection. The development and progression of sepsis is multi-factorial, and affects the cardiovascular, immunological and endocrine systems of the body. The complexity of sepsis makes the clinical study of sepsis and sepsis therapeutics difficult. Animal models have been developed in an effort to create reproducible systems for studying sepsis pathogenesis and preliminary testing of potential therapeutic agents. However, demonstrated benefit from a therapeutic agent in animal models has rarely been translated into success in human clinical trials. This review summarizes the common animal sepsis models and highlights how results of recent human clinical trials might affect their use.
引用
收藏
页码:854 / 865
页数:12
相关论文
共 107 条
[91]   ANTI-CACHECTIN TNF MONOCLONAL-ANTIBODIES PREVENT SEPTIC SHOCK DURING LETHAL BACTEREMIA [J].
TRACEY, KJ ;
FONG, Y ;
HESSE, DG ;
MANOGUE, KR ;
LEE, AT ;
KUO, GC ;
LOWRY, SF ;
CERAMI, A .
NATURE, 1987, 330 (6149) :662-664
[92]   Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels [J].
Turnbull, IR ;
Javadi, P ;
Buchman, TG ;
Hotchkiss, RS ;
Karl, IE ;
Coopersmith, CM .
SHOCK, 2004, 21 (02) :121-125
[93]   The 'cytokine profile': a code for sepsis [J].
Ulloa, L ;
Tracey, KJ .
TRENDS IN MOLECULAR MEDICINE, 2005, 11 (02) :56-63
[94]   Cytokines and anticytokines in the pathogenesis of sepsis [J].
van der Poll, T ;
van Deventer, SJH .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (02) :413-+
[95]   Interleukin-10 impairs host defense in murine pneumococcal pneumonia [J].
vanderPoll, T ;
Marchant, A ;
Keogh, CB ;
Goldman, M ;
Lowry, SF .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (05) :994-1000
[96]  
VANDERPOLL T, 1995, J IMMUNOL, V155, P5397
[97]   The dark side of C5A in sepsis [J].
Ward, PA .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (02) :133-142
[98]   Anti-complement strategies in experimental sepsis [J].
Ward, PA ;
Riedemann, NC ;
Guo, RF ;
Huber-Lang, M ;
Sarma, JV ;
Zetoune, FS .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2003, 35 (09) :601-603
[99]   Myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection [J].
Weighardt, H ;
Kaiser-Moore, S ;
Vabulas, RM ;
Kirschning, CJ ;
Wagner, H ;
Holzmann, B .
JOURNAL OF IMMUNOLOGY, 2002, 169 (06) :2823-2827
[100]   Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis [J].
Weighardt, H ;
Heidecke, CD ;
Westerholt, A ;
Emmanuilidis, K ;
Maier, S ;
Veit, M ;
Gerauer, K ;
Matevossian, E ;
Ulm, K ;
Siewert, JR ;
Holzmann, B .
ANNALS OF SURGERY, 2002, 235 (04) :560-567